The Wall Street Journal reports that Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals will pay $158 million to resolve claims related to the sales and marketing of its Risperdal antipsychotic drug.The settlement resolves a case brought by the state of Texas in 2004.Johnson & Johnson (NYSE:JNJ) has potential upside of 9.1% based on a current price of $64.98 and an average consensus analyst price target of $70.91.